Cristin-prosjekt-ID: 563167
Sist endret: 15. november 2017 15:31
Cristin-prosjekt-ID: 563167
Sist endret: 15. november 2017 15:31
Prosjekt

Integrated Novel Natural Product Discovery and Production Platform for Accelerated Biopharmaceutical Innovation from Microbial Biodiversity (INBioPharm)

prosjektleder

Alexander Wentzel
ved Bioteknologi og nanomedisin ved SINTEF AS

prosjekteier / koordinerende forskningsansvarlig enhet

  • SINTEF AS

Finansiering

  • TotalbudsjettNOK 27.575.000
  • Norges forskningsråd

    • Prosjektkode: 248885

Klassifisering

Vitenskapsdisipliner

Bioinformatikk • Biofarmasi • Bioteknologi

Emneord

Bioteknologi

HRCS-helsekategori

  • Kreft
  • Infeksjon

HRCS-forskningsaktivitet

  • 5.1 Legemidler

Kategorier

Prosjektkategori

  • Anvendt forskning

Tidsramme

Aktivt
Start: 1. mars 2016 Slutt: 30. juni 2020

Beskrivelse Beskrivelse

Tittel

Integrated Novel Natural Product Discovery and Production Platform for Accelerated Biopharmaceutical Innovation from Microbial Biodiversity (INBioPharm)

Populærvitenskapelig sammendrag

Bioactive chemicals produced by microorganisms, like bacteria and fungi, isolated from nature have been the source of most antibiotics in medical use today. However, the fact that many antibiotics are currently losing their function due to the rapid spreading of antibiotic resistance among pathogenic bacteria and that coincidently only very few new antibiotics have reached the market the last decades, craves for an increased effort and new technology for the more rapid discovery of new bioactive compounds and their development into medical drugs to cure life-threatening bacterial infections in the future, as well as to treat other deadly diseases, including cancer.

The INBioPharm project will develop a new, generic technology platform for the more efficient discovery of novel bioactive compounds with improved prospects to become medical products. A unique national collection of marine microorganisms at SINTEF/NTNU will be used as the basis for the development of different new, complementary molecular biology, analytical and screening methods and their combination into one platform that can access and exploit the huge potential of microorganisms in nature to synthesize useful bioactive natural products in a more efficient way. Central to this effort will be the development of the actinobacterium Streptomyces coelicolor into a microbial cell factory that is capable of producing diverse bioactive compounds of other natural microorganisms, including the huge majority of bacteria that cannot be cultivated in the laboratory, and the large number of compounds of cultivable bacteria that are not produced under laboratory conditions.

The INBioPharm project is funded by the Research Council of Norway with 27.5 million NOK as part of the new 'Centre for Digital Life Norway' established in 2016.

Vitenskapelig sammendrag

Bioactive chemicals produced by microorganisms, like bacteria and fungi, isolated from nature have been the source of most antibiotics in medical use today. However, the fact that many antibiotics are currently losing their function due to the rapid spreading of antibiotic resistance among pathogenic bacteria and that coincidently only very few new antibiotics have reached the market the last decades, craves for an increased effort and new technology for the more rapid discovery of new bioactive compounds and their development into medical drugs to cure life-threatening bacterial infections in the future, as well as to treat other deadly diseases, including cancer.

The INBioPharm project will develop a new, generic technology platform for the more efficient discovery of novel bioactive compounds with improved prospects to become medical products. A unique national collection of marine microorganisms at SINTEF/NTNU will be used as the basis for the development of different new, complementary molecular biology, analytical and screening methods and their combination into one platform that can access and exploit the huge potential of microorganisms in nature to synthesize useful bioactive natural products in a more efficient way. Central to this effort will be the development of the actinobacterium Streptomyces coelicolor into a microbial cell factory that is capable of producing diverse bioactive compounds of other natural microorganisms, including the huge majority of bacteria that cannot be cultivated in the laboratory, and the large number of compounds of cultivable bacteria that are not produced under laboratory conditions.

The INBioPharm project is funded by the Research Council of Norway with 27.5 million NOK as part of the new 'Centre for Digital Life Norway' established in 2016.

Metode

Functional (Meta)Genomics, Systems Biology, High-Throughput Screening, Mass Spectrometry, Bioinformatics, Molecular Biology, Sequence- and Function-based Bioprospecting, Bioprocess Technology/Fermentation

Utstyr

Fermentation facilities, High-Throughput Screening robots, Mass Spectrometry instruments, Next-gen Sequencers, High performance computers, Bioinformatics software

prosjektdeltakere

prosjektleder
Aktiv cristin-person

Alexander Wentzel

  • Tilknyttet:
    Prosjektleder
    ved Bioteknologi og nanomedisin ved SINTEF AS

Giang-Son Nguyen

  • Tilknyttet:
    Prosjektdeltaker
    ved Bioteknologi og nanomedisin ved SINTEF AS

Trond Erling Ellingsen

  • Tilknyttet:
    Prosjektdeltaker
    ved Bioteknologi og nanomedisin ved SINTEF AS

Håvard Sletta

  • Tilknyttet:
    Prosjektdeltaker
    ved Bioteknologi og nanomedisin ved SINTEF AS

Anna Nordborg

  • Tilknyttet:
    Prosjektdeltaker
    ved Bioteknologi og nanomedisin ved SINTEF AS
1 - 5 av 11 | Neste | Siste »

Resultater Resultater

A genome-scale metabolic model for Streptomyces coelicolor.

Kumelj, Tjasa; Sulheim, Snorre; Wentzel, Alexander; Almaas, Eivind. 2017, Advanced course on Metabolic engineering and Systems Biology. SINTEF, NTNUPoster

Extended GEM of Streptomyces coelicolor for production of secondary metabolites.

Kumelj, Tjasa; Sulheim, Snorre; Wentzel, Alexander; Almaas, Eivind. 2017, International conference on systems biology 2017 (ICSB 2017). SINTEF, NTNUVitenskapelig foredrag

A genome-scale metabolic model for Streptomyces coelicolor.

Sulheim, Snorre; Kumelj, Tjasa; Wentzel, Alexander; Almaas, Eivind. 2017, Advanced course on Metabolic engineering and Systems Biology. SINTEF, NTNUPoster

A genome-scale metabolic model for Streptomyces coelicolor.

Sulheim, Snorre; Kumelj, Tjasa; Wentzel, Alexander; Almaas, Eivind. 2017, Lunsj-seminar. SINTEF, NTNUVitenskapelig foredrag

A genome-scale metabolic model for Streptomyces coelicolor.

Sulheim, Snorre; Kumelj, Tjasa; Wentzel, Alexander; Almaas, Eivind. 2017, Modelling living systems - From foundational problems to applications. SINTEF, NTNUVitenskapelig foredrag
1 - 5 av 22 | Neste | Siste »